Targeting unique disease-specific peptide HLA complexes is an essential input for filling immunotherapeutic drug discovery pipelines. Pure MHC’s Business Development plan makes it easy to partner with mutually favorable terms and creative flexibility to meet your specific corporate needs.
Available TCRm mAb
|Ovarian including Cisplatin Resistant||WNV|
and other cancers”
Source Proteins (relative to multiple cancers)
Contact Us to learn more.